spacer
home > epc
PUBLICATIONS

European Pharmaceutical Contractor

 

Published quarterly, European Pharmaceutical Contractor (EPC) covers the essential contract research issues between pharma companies and their CRO partners. The title, which is integrated within International Clinical Trials (ICT) magazine, offers a strategic view of the drug development industry giving its pharma, biotech and CRO readership expert insight and analysis on the sponsor-service provider landscape.

EPC focuses on key trends, concerns and developments in contract research operations across the drug development spectrum, from preclinical to post-marketing. It explores the shifting collaborative needs and practical implications for sponsors and their contract partners, with the emphasis on building and managing effective collaborations.

Prompted by the synergies between outsourcing and trial operations, EPC joined forces with sister brand ICT in late-2015, in a move that brings added value to both brands. With EPC now an inserted edition within ICT, industry practitioners across these complementary subject areas now have unrivalled access to a wealth of shared views and analyses.

 

For further information please contact:

Advertising
Nick Matthews

Editorial
Thanh Thanh Lam

We're also on Twitter! Follow us @EPCmagazine

The latest digital edition of EPC can be viewed here
 

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.


epc
 
 
Featured in this issue
Business and Finance
Drug Prices

Adding Value


Putting a price tag on drugs is a challenge but by implementing two increasingly common pricing strategies, it is possible to satisfy both seller and buyer, claim ERTs Stephen Raymond and Matthew Reaney.
Marketplace & Business
M&A Activity Report

Across the Border


There is a noticeable shift towards acquiring in growing markets overseas, and investment in personalised medicine EPC summaries these twin trends within M&A activity.
  Legal & Regulatory
Clinical Evaluation

Conform to the Norm: Part 1


In this first of a two-part article, Terry Winchell at GCP Innovative Dynamics offers an in-depth analysis of the FDA clinical investigator disqualification process, including early beginnings and how the FDA interprets its role.

spacer



Published quarterly in
February, May,
August and November


 

Industry Events

4th BioLogistics Summit

27-29 June 2016, San Francisco, CA

1 summit for solutions on the storage, handling, and distribution of biologic based products and materials as they are transported.
More info >>

 
News and Press Releases

Merck Builds on Leading Viral and Gene Therapy Service Offering with Capacity Expansions

Merck, a leading science and technology company, today announced an expansion of its Carlsbad, California facility to meet growing demand for viral and gene therapy products.
More info >>

air transport logo

 

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement